{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:16Z","timestamp":1787020156225,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12883-016-0610-7","type":"journal-article","created":{"date-parts":[[2016,6,6]],"date-time":"2016-06-06T21:20:14Z","timestamp":1465248014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Robert A","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Slawek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Dohin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Surmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Asgharnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"key":"610_CR1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/jnnp.2007.136895","volume":"79","author":"SE Starkstein","year":"2008","unstructured":"Starkstein SE, Leentjens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;79:1088\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"610_CR2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1037\/a0022851","volume":"30","author":"KR Bogart","year":"2011","unstructured":"Bogart KR. Is apathy a valid and meaningful symptom or syndrome in Parkinson\u2019s disease? A critical review. Health Psychol. 2011;30:386\u2013400.","journal-title":"Health Psychol"},{"key":"610_CR3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/mds.26208","volume":"30","author":"MG Brok den","year":"2015","unstructured":"den Brok MG, van Dalen JW, van Gool WA, van Charante EP M, de Bie RM, Richard E. Apathy in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2015;30:759\u201369.","journal-title":"Mov Disord"},{"key":"610_CR4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.parkreldis.2015.07.007","volume":"21","author":"GD Cochrane","year":"2015","unstructured":"Cochrane GD, Rizvi S, Abrantes AM, Crabtree B, Cahill J, Friedman JH. The association between fatigue and apathy in patients with either Parkinson\u2019s disease or multiple sclerosis. Parkinsonism Relat Disord. 2015;21:1093\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"610_CR5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","volume":"24","author":"P Barone","year":"2009","unstructured":"Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord. 2009;24:1641\u20139.","journal-title":"Mov Disord"},{"key":"610_CR6","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00415-012-6557-8","volume":"259","author":"A Antonini","year":"2012","unstructured":"Antonini A, Barone P, Marconi R, Morgante L, Zappulla S, Pontieri FE, et al. The progression of non-motor symptoms in Parkinson\u2019s disease and their contribution to motor disability and quality of life. J Neurol. 2012;259:2621\u201331.","journal-title":"J Neurol"},{"key":"610_CR7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","volume":"14","author":"J Pagonabarraga","year":"2015","unstructured":"Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson\u2019s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015;14:518\u201331.","journal-title":"Lancet Neurol"},{"key":"610_CR8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.expneurol.2012.04.025","volume":"236","author":"CA Brown","year":"2012","unstructured":"Brown CA, Campbell MC, Karimi M, Tabbal SD, Loftin SK, Tian LL, et al. Dopamine pathway loss in nucleus accumbens and ventral tegmenal area predicts apathetic behavior in MPTP-lesioned monkeys. Exp Neurol. 2012;236:190\u20137.","journal-title":"Exp Neurol"},{"key":"610_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-015-0377-y","volume":"75","author":"JP Elshoff","year":"2015","unstructured":"Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson\u2019s disease and restless legs syndrome. Drugs. 2015;75:487\u2013501.","journal-title":"Drugs"},{"key":"610_CR10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90\u20139.","journal-title":"Mov Disord"},{"key":"610_CR11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0b013e3181c0d416","volume":"73","author":"P Martinez-Martin","year":"2009","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod-Artal FJ, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology. 2009;73:1584\u201391.","journal-title":"Neurology"},{"key":"610_CR12","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord. 2007;22:1901\u201311.","journal-title":"Mov Disord"},{"key":"610_CR13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","volume":"19","author":"KR Chaudhuri","year":"2013","unstructured":"Chaudhuri KR, Martinez-Martin P, Antonini A, Brown RG, Friedman JH, Onofrj M, et al. Rotigotine and specific non-motor symptoms of Parkinson\u2019s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19:660\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"610_CR14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1176\/jnp.4.2.134","volume":"4","author":"SE Starkstein","year":"1992","unstructured":"Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci. 1992;4:134\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"610_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-1781(91)90040-V","volume":"38","author":"RS Marin","year":"1991","unstructured":"Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38:143\u201362.","journal-title":"Psychiatry Res"},{"key":"610_CR16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mds.21949","volume":"23","author":"V Czernecki","year":"2008","unstructured":"Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23:964\u20139.","journal-title":"Mov Disord"},{"key":"610_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1176\/jnp.2009.21.2.144","volume":"21","author":"RG Robinson","year":"2009","unstructured":"Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2009;21:144\u201351.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"610_CR18","unstructured":"Siu CO, Gordon Lan KK. Flexible interim analysis method for sample size re-estimation and early stopping: a conditional power approach. In: Annual Meeting of the American Statistical Association: August 5-9 2001; 2001"},{"key":"610_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.64.5.676","volume":"64","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64:676\u201382.","journal-title":"Arch Neurol"},{"key":"610_CR20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","volume":"68","author":"RL Watts","year":"2007","unstructured":"Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272\u20136.","journal-title":"Neurology"},{"key":"610_CR21","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","volume":"22","author":"N Giladi","year":"2007","unstructured":"Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH, et al. Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22:2398\u2013404.","journal-title":"Mov Disord"},{"key":"610_CR22","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/mds.22229","volume":"23","author":"AF Leentjens","year":"2008","unstructured":"Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Apathy and anhedonia rating scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2008;23:2004\u201314.","journal-title":"Mov Disord"},{"key":"610_CR23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/ene.12757","volume":"22","author":"A Antonini","year":"2015","unstructured":"Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, et al. Effects of rotigotine transdermal patch in patients with Parkinson\u2019s disease presenting with non-motor symptoms\u2009\u2212\u2009results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015;22:1400\u20137.","journal-title":"Eur J Neurol"},{"key":"610_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","volume":"31","author":"AF Leentjens","year":"2009","unstructured":"Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson\u2019s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31:89\u201398.","journal-title":"Clin Ther"},{"key":"610_CR25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40266-015-0264-y","volume":"32","author":"J P\u00e9rez-P\u00e9rez","year":"2015","unstructured":"P\u00e9rez-P\u00e9rez J, Pagonabarraga J, Mart\u00ednez-Horta S, Fern\u00e1ndez-Bobadilla R, Sierra S, Pascual-Sedano B, et al. Head-to-head comparison of the neuropsychiatric effect of dopamine agonists in Parkinson\u2019s disease: a prospective, cross-sectional study in non-demented patients. Drugs Aging. 2015;32:401\u20137.","journal-title":"Drugs Aging"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0610-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:51:03Z","timestamp":1498305063000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-016-0610-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s12883-016-0610-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]},"article-number":"90"}}